Patent US4824660A successfully refreshed from Google Patents.
US4824660A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of determining the viability of tissue in an organism
Assignee: ANGELLO PAUL S 1858 PALISADES TERRACE DRIVE LAKE OSWEGO OREGON 97034
•
Filing: 1985-06-06
•
Granted: 1989-04-25
•
Expires: 2005-06-06
Abstract
Abstract A method of determining the viability of tissue in a region of an organism comprises the steps of introducing an ATP repleting agent into the region and monitoring the region to determine its effect on T1-201 distribution in the region. The capability of viable tissue to synthesize ATP and increase its ATP stores provides an indication of the viability of the tissue in the region. In a preferred embodiment of the method, ribose, which is a high energy phosphate precursor and an ATP repleting agent, is introduced into heart tissue that is being monitored by T1-201 scintigraphy. The ribose increases the rate and extent of T1-201 distribution in the heart tissue, thereby allowing the determination of viable "stunned" heart tissue. That viable tissue is distinguishable from nonviable tissue is attributed to the capability of the former to synthesize ATP and increase its ATP stores in response to the administration of the ATP repleting agent. Such manipulation of ATP stores in a region of tissue effects a detectable change in T1-201 distribution in that region. The method permits, therefore, the rapid determination of viable heart tissue.R
Inventors
- 👤 Debra A. Angello
- 👤 Richard A. Wilson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 02:33
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0493; A61K2123/00
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
89 words
A method of determining the viability of a region of heart tissue, comprising: introducing a high energy phosphate precursor agent into the region of heart tissue; introducing a blood flow marking medium into the circulatory system that supplies blood to the region of heart tissue; and performing noninvasive myocardial imaging to monitor the amount of blood flow marking medium appearing in the region of heart tissue in response to the presence of the precursor agent, thereby to provide an indication of the viability of the region of heart tissue.
Claim 2
Independent Claim
89 words
A method of determining the viability of a region of heart tissue, comprising: introducing a high energy phosphate precursor agent into the region of heart tissue; introducing a blood flow marking medium into the circulatory system that supplies blood to the region of heart tissue; and performing noninvasive myocardial imaging to monitor the amount of blood flow marking medium appearing in the region of heart tissue in response to the presence of the precursor agent, thereby to provide an indication of the viability of the region of heart tissue.
Claim 3
Dependent Claim
28 words
The method of claim 1 in which the precursor agent is selected from the group consisting essentially of pentoses, pentitols, adenosine, hypoxanthine, inosine, l-glutamate, l-aspartate, l-arginine, and l-ornithine.
Claim 4
Dependent Claim
14 words
The method of claim 1 in which the blood flow marking medium is Tl-201.
Claim 5
Dependent Claim
47 words
The method of claim 3 in which the amount of Tl-201 present in the region of heart tissue is monitored by: counting the number of radioactive emissions produced by the Tl-201; and correlating the number of measured emissions to the viability of the region of heart tissue.
Claim 6
Dependent Claim
16 words
The method of claim 1 in which the heart tissue is that of a human being.
Claim 7
Independent Claim
88 words
A method of determining the viability of a region of heart tissue, comprising: introducing a ATP repleting agent into the region of heart tissue; introducing a blood flow marking medium into the circulatory system that supplies blood to the region of heart tissue; and performing noninvasive myocardial imaging to determine the amount of blood flow marking medium appearing in the region of heart tissue in response to the presence of the ATP repleting agent, thereby to provide an indication of the viability of the region of heart tissue.
Claim 8
Independent Claim
88 words
A method of determining the viability of a region of heart tissue, comprising: introducing a ATP repleting agent into the region of heart tissue; introducing a blood flow marking medium into the circulatory system that supplies blood to the region of heart tissue; and performing noninvasive myocardial imaging to determine the amount of blood flow marking medium appearing in the region of heart tissue in response to the presence of the ATP repleting agent, thereby to provide an indication of the viability of the region of heart tissue.
Claim 9
Dependent Claim
17 words
The method of claim 6 in which the ATP repleting agent comprises a high energy phosphate precursor.
Claim 10
Dependent Claim
29 words
The method of claim 6 in which the ATP repleting agent is selected from the group consisting essentially of pentoses, pentitols, adenosine, hypoxanthine, inosine, l-glutamate, l-aspartate, l-arginine, and l-ornithine.
Claim 11
Dependent Claim
14 words
The method of claim 6 in which the blood flow marking medium is Tl-201.
Claim 12
Dependent Claim
14 words
The method of claim 1 in which the blood flow marking medium is Rb-82.
Claim 13
Dependent Claim
16 words
The method of claim 1 in which the heart tissue is that of a nonhuman animal.
Claim 14
Dependent Claim
12 words
The method of claim 3 in which the precursor agent is ribose.
Claim 15
Dependent Claim
14 words
The method of claim 6 in which the blood flow marking medium is Rb-82.
Claim 16
Dependent Claim
16 words
The method of claim 6 in which the heart tissue is that of a human body.
Claim 17
Dependent Claim
16 words
The method of claim 6 in which the heart tissue is that of a nonhuman animal.
Claim 18
Dependent Claim
14 words
The method of claim 7 in which the high energy phosphate precursor is ribose.
Claim 19
Dependent Claim
13 words
The method of claim 6 in which the ATP repleting agent is ribose.
Claim 20
Dependent Claim
13 words
The method of claim 9 in which the ATP repleting agent is ribose.
Claim 21
Independent Claim
81 words
The method of determining the viability of a region of heart tissue, comprising: introducing a quantity of ribose into the region of heart tissue; introducing a blood flow marking medium into the circulatory system that supplies blood to the region of heart tissue; and monitoring the amount of blood flow marking medium appearing in the region of heart tissue in response to the presence of the ribose, thereby to provide an indication of the viability of the region of heart tissue.
Claim 22
Independent Claim
81 words
The method of determining the viability of a region of heart tissue, comprising: introducing a quantity of ribose into the region of heart tissue; introducing a blood flow marking medium into the circulatory system that supplies blood to the region of heart tissue; and monitoring the amount of blood flow marking medium appearing in the region of heart tissue in response to the presence of the ribose, thereby to provide an indication of the viability of the region of heart tissue.
Claim 23
Dependent Claim
14 words
The method of claim 19 in which the blood flow marking medium is Tl-201.
Claim 24
Dependent Claim
48 words
The method of claim 20 in which the amount of Tl-201 present in the region of the heart tissue is monitored by: counting the number of radioactive emissions produced by the Tl-201; and correlating the number of measured emissions to the viability of the region of heart tissue.
Claim 25
Dependent Claim
14 words
The method of claim 19 in which the blood flow marking medium is Rb-82.
Claim 26
Dependent Claim
16 words
The method of claim 19 in which the heart tissue is that of a nonhuman animal.
Claim 27
Dependent Claim
16 words
The method of claim 19 in which the heart tissue is that of a human being.
Claim 28
Dependent Claim
25 words
The method of claim 19 in which the amount of Tl-201 present in the region of heart tissue is monitored by performing noninvasive myocardial imaging.
References Cited (Backward Citations)
US4364922A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-04-24 | 1992-10-24 | 1993-04-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-04-24 | 1996-10-24 | 1997-04-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-04-24 | 2000-10-24 | 2001-04-25 | $7700.00 | Window Closed / Lapsed |